drugset / Trial / NCT04660812
An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.
RandomizedParallel-groupSingle-blindTreatment
Summary
This randomized phase 1b/2 open-label study will evaluate the antitumour activity and safety of etrumadenant (AB928) treatment combinations in participants with metastatic colorectal cancer.
Timeline
- Start
- 2021-05-10
- Primary completion
- 2025-09-05
- Completion
- 2025-09-05
Outcome
Met primary endpoint
release “ARC-9 mCRC Study, Etrumadenant Plus Zimberelimab, FOLFOX Chemotherapy and Bevacizumab Significantly Reduced the Risk of Death by 63% and Risk of Disease Progression by 73%” arcusbio.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etrumadenant | Small molecule | — | Oral |
| Subject | Quemliclustat | Small molecule | — | Intravenous |
| Comparator | Regorafenib | Small molecule | — | Oral |
| Subject | Zimberelimab | Monoclonal antibody | — | Intravenous |
| Background | Bevacizumab | Monoclonal antibody | — | Intravenous |